NEW YORK, Dec 2 (Reuters) - CVS Health will pay $37.76 million to settle allegations it dispensed too many insulin pens to patients, and then obtained improper reimbursements from Medicare, Medicaid ...

CVS Health ( CVS) has reached a settlement with the U.S. government, requiring the company to pay $37.76M to resolve claims that it overbilled government healthcare programs for insulin pens.

California lawmakers and Gov. Gavin Newsom approved new laws impacting pet owners, landlords, school bathrooms and more.

The Go-Pen insulin pen. [Image courtesy of the company] Go-Pen announced today on social media that it received CE mark approval for its user-fillable insulin pen. The Denmark-based company said on ...

A proposed insulin glargine biosimilar (Basalin) demonstrated comparable efficacy, safety, and immunogenicity to the originator product (Lantus) in adults living with type 2 diabetes, according to ...

California Governor Gavin Newsom today announced that CalRx® biosimilar insulin glargine pens will be available to consumers in California beginning January 1, 2026. This launch marks a significant ...

Litigation over Medtronic Plc’s alleged scheme to avoid $100 million in deal payments by sabotaging sales of a reusable insulin pen ended with an anticlimax Monday. The order formally dismissing the ...

California’s CalRx insulin pens will launch Jan. 1 at $11 each, or $55 for a five-pack The state has invested $100 million to lower insulin costs The effort could save patients $2,000 to $4,000 a year ...

SACRAMENTO, CA – Setting a national precedent, California will sell its own state-branded insulin, making life-saving diabetes medication affordable for millions. Governor Gavin Newsom announced that ...

LOS ANGELES (AP) — Gov. Gavin Newsom said Thursday that California will begin selling affordable insulin under its own label on Jan. 1, nearly three years after he first announced a partnership to ...

The state's top officials just announced a landmark initiative to slash insulin prices, beginning on this date. In a first-of-its-kind move to address the high cost of insulin and improve access for ...